VolitionRx (NYSE:VNRX) Receives New Coverage from Analysts at StockNews.com

Posted by Donna Armstrong on Apr 29th, 2024

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research note issued to investors on Friday. The brokerage issued a sell rating on the stock.

Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $2.50 target price on shares of VolitionRx in a research note on Wednesday, March 27th.

Get Our Latest Report on VNRX

VolitionRx Stock Up 2.6 %

Shares of VNRX opened at $0.91 on Friday. VolitionRx has a 52-week low of $0.55 and a 52-week high of $2.10. The firm’s fifty day moving average is $0.84 and its two-hundred day moving average is $0.84. The stock has a market cap of $74.99 million, a PE ratio of -1.79 and a beta of 1.35.

VolitionRx (NYSE:VNRX – Get Free Report) last announced its earnings results on Monday, March 25th. The company reported ($0.11) earnings per share (EPS) for the quarter. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.50 million. As a group, research analysts anticipate that VolitionRx will post -0.4 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new stake in VolitionRx Limited (NYSE:VNRX – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx at the end of the most recent quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.